Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force

Sarah B. Whittle, Katharine Offer, Ryan D. Roberts, Amy LeBlanc, Cheryl London, Robbie G. Majzner, Alex Y. Huang, Peter Houghton, E. Alejandro Sweet Cordero, Patrick J. Grohar, Michael Isakoff, Michael W. Bishop, Elizabeth Stewart, Emily K. Slotkin, Emily Greengard, Scott C. Borinstein, Fariba Navid, Richard Gorlick, Katherine A. Janeway, Damon R. ReedPooja Hingorani

Research output: Contribution to journalArticlepeer-review

Abstract

Osteosarcoma is the most common bone tumor in children and young adults. Metastatic and relapsed disease confer poor prognosis, and there have been no improvements in outcomes for several decades. The disease's biological complexity, lack of drugs developed specifically for osteosarcoma, imperfect preclinical models, and limits of existing clinical trial designs have contributed to lack of progress. The Children's Oncology Group Bone Tumor Committee established the New Agents for Osteosarcoma Task Force to identify and prioritize agents for inclusion in clinical trials. The group identified multitargeted tyrosine kinase inhibitors, immunotherapies targeting B7-H3, CD47-SIRPα inhibitors, telaglenastat, and epigenetic modifiers as the top agents of interest. Only multitargeted tyrosine kinase inhibitors met all criteria for frontline evaluation and have already been incorporated into an upcoming phase III study concept. The task force will continue to reassess identified agents of interest as new data become available and evaluate novel agents using this method.

Original languageEnglish (US)
Article numbere29188
JournalPediatric Blood and Cancer
Volume68
Issue number9
DOIs
StatePublished - Sep 2021

Keywords

  • chemotherapy
  • clinical trials
  • metastasis
  • osteosarcoma
  • relapsed
  • therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force'. Together they form a unique fingerprint.

Cite this